Accent Therapeutics launches to target the epitranscriptomic RNA code in cancer

With $40 million series A funding, the start-up will develop inhibitors of proteins that make chemical modifications to RNA

via Chemical & Engineering News: Biological SCENE https://ift.tt/2rLR2LB